Inés de Mir-Messa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Inés de Mir-Messa has a total of 168 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Moreno-Galdó
Department of Pediatrics Universitat Autònoma de Barcelona Barcelona Spain
4 shared publications - Verónica Sanz-Santiago
Department of Paediatric Pulmonology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
4 shared publications - Alejandro López-Neyra
Department of Paediatric Pulmonology, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
3 shared publications - Ana Díez-Izquierdo
Paediatric Pulmonology, Allergology and Cystic Fibrosis Unit, Hospital Universitario Materno Infantil Vall d'Hebron, Vall d'Hebron Research Institute (VHIR), Barcelona, Spain
3 shared publications - María Araceli Caballero-Rabasco
Hospital del Mar, 08003 Barcelona, Spain
3 shared publications A. Salcedo Posadas
Sección de Neumología, Hospital Maternoinfantil Gregorio Marañón, Madrid, España
2 shared publications
Latest Publications
- Open Access
- 4 June 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2600265
Home-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial
Introduction: While high-intensity interval training (HIIT) has shown effectiveness in improving cardiorespiratory fitness (CRF) across various chronic respiratory diseases, its impacts on individuals with post-infectious bronchiolitis obliterans (PIBO) remain unexplored. Aim: To assess the effects of a home-based remotely-supervised HIIT programme on CRF, clinical and functional variables in patients with PIBO. Methods: Participants of this assessor-blinded, multicentre, randomized controlled trial were individuals with PIBO aged 6 to 20 years. An exercise group (EXE) underwent two 40-min sessions of HIIT remotely supervised in real time per week. Sessions were continued for 16 weeks. The control group (CON) adhered to general physical activity recommendations. The primary outcome was peak oxygen consumption (VO 2 peak), time to ventilatory threshold (VT 1 ), percentage of VO 2 at VT 1 , and ventilatory equivalent for carbon dioxide, determined via cardiopulmonary exercise testing on a treadmill. Secondary outcomes were lung function (spirometry), muscle strength (dynamometry), functional capacity (30-second Sit-To-Stand test), body mass index, and Saint George Respiratory Questionnaire. Results: Fifty-one PIBO patients were enrolled (EXE=25; CON=26) (mean age 13.3±4.2 years; females 49%; FEV 1 −3.56±1.28 (z-score); VO 2 peak 36.8±8.6 mL.kg −1 .min −1 ). The HIIT intervention resulted in improvements in VO 2 peak (Δ=3.39; p=0.04), time (min) to VT 1 (Δ=1.05; p=0.04), and in the number of repetitions in the 30s-STS (Δ=2.21; p=0.04). No differences were found in the other variables. Conclusions: Our real-time, remotely-supervised HIIT intervention was effective at significantly increasing CRF and functional capacity in children and adolescents with PIBO.
- 4 June 2026
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 68 (4) , 2600265
Open AccessHome-based remotely-supervised high-intensity interval training and cardiorespiratory fitness in children and adolescents with post-infectious bronchiolitis obliterans: a randomized controlled trial
Introduction: While high-intensity interval training (HIIT) has shown effectiveness in improving cardiorespiratory fitness (CRF) across various chronic respiratory diseases, its impacts on individuals with post-infectious bronchiolitis obliterans (PIBO) remain unexplored. Aim: To assess the effects of a home-based remotely-supervised HIIT programme on CRF, clinical and functional variables in patients with PIBO. Methods: Participants of this assessor-blinded, multicentre, randomized controlled trial were individuals with PIBO aged 6 to 20 years. An exercise group (EXE) underwent two 40-min sessions of HIIT remotely supervised in real time per week. Sessions were continued for 16 weeks. The control group (CON) adhered to general physical activity recommendations. The primary outcome was peak oxygen consumption (VO 2 peak), time to ventilatory threshold (VT 1 ), percentage of VO 2 at VT 1 , and ventilatory equivalent for carbon dioxide, determined via cardiopulmonary exercise testing on a treadmill. Secondary outcomes were lung function (spirometry), muscle strength (dynamometry), functional capacity (30-second Sit-To-Stand test), body mass index, and Saint George Respiratory Questionnaire. Results: Fifty-one PIBO patients were enrolled (EXE=25; CON=26) (mean age 13.3±4.2 years; females 49%; FEV 1 −3.56±1.28 (z-score); VO 2 peak 36.8±8.6 mL.kg −1 .min −1 ). The HIIT intervention resulted in improvements in VO 2 peak (Δ=3.39; p=0.04), time (min) to VT 1 (Δ=1.05; p=0.04), and in the number of repetitions in the 30s-STS (Δ=2.21; p=0.04). No differences were found in the other variables. Conclusions: Our real-time, remotely-supervised HIIT intervention was effective at significantly increasing CRF and functional capacity in children and adolescents with PIBO.
- Open Access
- 19 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0335399
Protocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM)
Introduction: Children with severe eosinophilic asthma are at an increased risk of severe exacerbations, medication side effects, impaired lung function, and significantly reduced quality of life. The advent of biologic agents aimed at eosinophilic pathways has significantly improved management options for patients with severe asthma. Mepolizumab, an anti-interleukin-5 monoclonal antibody, was approved in 2018 as an add-on maintenance treatment for patients with severe eosinophilic asthma aged ≥6 years of age. Mepolizumab’s efficacy and safety is well documented in adults, but paediatric data remain limited. This real-world observational study will evaluate the long-term safety and efficacy of mepolizumab in children and adolescents, including those with comorbidities and on concomitant medications to provide a clearer picture of its performance in everyday clinical practice. Methods and analysis: Design: CASAM is an open label, multinational (Spain and United Kingdom), multicenter (15 Spanish and 6 UK public institutions) observational cohort study. Sample size: 150 paediatric patients on mepolizumab for SA between 6–17 years of age will be enrolled. Study Duration: Study will be conducted over 36 months (12 months pre mepolizumab initiation and 24 months after initiation). Data Collection: Pseudonymized data (prospective and retrospective) from medical charts will be collected and entered in the electronic case report forms (eCRFs) of the electronic data capture (EDC) system. Primary Outcome: To compare the rates of clinically significant asthma exacerbations in the pre-exposure and the 12-month post-exposure period with mepolizumab treatment. Protocol Version: CASAM Study_Protocol_V2.0_16th November 2023 KCH Registration details: The study is registered with ClinicalTrials.gov (NCT05139381), IRAS number 306475.
- 19 December 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (12) , e0335399
Open AccessProtocol for an open labelled observational study in children & adolescents with severe asthma with an eosinophilic phenotype treated with mepolizumab (CASAM)
Introduction: Children with severe eosinophilic asthma are at an increased risk of severe exacerbations, medication side effects, impaired lung function, and significantly reduced quality of life. The advent of biologic agents aimed at eosinophilic pathways has significantly improved management options for patients with severe asthma. Mepolizumab, an anti-interleukin-5 monoclonal antibody, was approved in 2018 as an add-on maintenance treatment for patients with severe eosinophilic asthma aged ≥6 years of age. Mepolizumab’s efficacy and safety is well documented in adults, but paediatric data remain limited. This real-world observational study will evaluate the long-term safety and efficacy of mepolizumab in children and adolescents, including those with comorbidities and on concomitant medications to provide a clearer picture of its performance in everyday clinical practice. Methods and analysis: Design: CASAM is an open label, multinational (Spain and United Kingdom), multicenter (15 Spanish and 6 UK public institutions) observational cohort study. Sample size: 150 paediatric patients on mepolizumab for SA between 6–17 years of age will be enrolled. Study Duration: Study will be conducted over 36 months (12 months pre mepolizumab initiation and 24 months after initiation). Data Collection: Pseudonymized data (prospective and retrospective) from medical charts will be collected and entered in the electronic case report forms (eCRFs) of the electronic data capture (EDC) system. Primary Outcome: To compare the rates of clinically significant asthma exacerbations in the pre-exposure and the 12-month post-exposure period with mepolizumab treatment. Protocol Version: CASAM Study_Protocol_V2.0_16th November 2023 KCH Registration details: The study is registered with ClinicalTrials.gov (NCT05139381), IRAS number 306475.
- Open Access
- 6 August 2025
- Published by Taylor & Francis in Journal of Asthma
- p. 1-12
Impact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthma
Age of asthma onset is critical for determining heterogeneous asthma phenotypes. How onset and duration affect therapeutic response is not well understood. Phase 3 QUEST (NCT02414854) and open-label extension TRAVERSE (NCT02134028) studies demonstrated dupilumab's efficacy up to three years in patients ≥12 years with uncontrolled, moderate-to-severe asthma. We assessed how age of asthma onset and asthma duration affect clinical efficacy of dupilumab in patients with moderate-to-severe type 2 inflammatory asthma. This post hoc analysis included patients with type 2 asthma from QUEST who enrolled in TRAVERSE. Annualized severe exacerbation rates (AER), change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV1), and five-item Asthma Control Questionnaire (ACQ-5) score were assessed according to asthma age of onset (40 years) and duration (1 (TRAVERSE Week 96 change from PSBL range, 0.20-0.44 L), and reduced ACQ-5 scores (TRAVERSE Week 48 change from PSBL range, -1.63 to -1.84). In patients who received placebo during QUEST, treatment with dupilumab in TRAVERSE improved AER, FEV1, and ACQ-5 in all subgroups. In patients with uncontrolled, moderate-to-severe type 2 asthma, treatment with dupilumab provides sustained, long-term exacerbation rate reductions and improvements in lung function and asthma control, across all subgroups, with higher reductions in AER and improvements in pre-bronchodilator FEV1 seen in patients with later onset or longer duration.
- 6 August 2025
- Published by Taylor & Francis in Journal of Asthma
- p. 1-12
Open AccessImpact of asthma age of onset or duration on efficacy of dupilumab in moderate-to-severe type 2 asthma
Age of asthma onset is critical for determining heterogeneous asthma phenotypes. How onset and duration affect therapeutic response is not well understood. Phase 3 QUEST (NCT02414854) and open-label extension TRAVERSE (NCT02134028) studies demonstrated dupilumab's efficacy up to three years in patients ≥12 years with uncontrolled, moderate-to-severe asthma. We assessed how age of asthma onset and asthma duration affect clinical efficacy of dupilumab in patients with moderate-to-severe type 2 inflammatory asthma. This post hoc analysis included patients with type 2 asthma from QUEST who enrolled in TRAVERSE. Annualized severe exacerbation rates (AER), change from parent study baseline (PSBL) in pre-bronchodilator forced expiratory volume in 1 s (FEV1), and five-item Asthma Control Questionnaire (ACQ-5) score were assessed according to asthma age of onset (40 years) and duration (1 (TRAVERSE Week 96 change from PSBL range, 0.20-0.44 L), and reduced ACQ-5 scores (TRAVERSE Week 48 change from PSBL range, -1.63 to -1.84). In patients who received placebo during QUEST, treatment with dupilumab in TRAVERSE improved AER, FEV1, and ACQ-5 in all subgroups. In patients with uncontrolled, moderate-to-severe type 2 asthma, treatment with dupilumab provides sustained, long-term exacerbation rate reductions and improvements in lung function and asthma control, across all subgroups, with higher reductions in AER and improvements in pre-bronchodilator FEV1 seen in patients with later onset or longer duration.
- Open Access
- 17 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Cardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study
Background: Post-infectious bronchiolitis obliterans (PIBO) arises after lower respiratory tract infection during childhood and is marked by impaired lung function. Despite possible impacts on exercise capacity, cardiorespiratory fitness in PIBO patients remain largely unknown. This study aimed to examine cardiorespiratory fitness and identify possible demographic and clinical–functional associations. Methods: The following variables were examined in a multicentre, cross-sectional study conducted in clinically stable PIBO patients aged 6–20 years: cardiorespiratory fitness (exercise testing), lung function (spirometry and impulse oscillometry), muscle strength (handgrip, upper and lower extremities), functional capacity (30-s sit-to-stand (STS) test), physical activity level (physical activity questionnaire adolescents and children; PAQ-A-C), body mass index (BMI), quality of life (Saint George's respiratory questionnaire; SGRQ) and dyspnoea perception (modified Medical Research Council scale). Results: 51 patients were enrolled (mean age 13.2±4.2 years, 49% female). BMI z-score was 0.06±1.20. Lung function tests indicated moderate-to-severe obstruction (forced expiratory volume in 1 s (FEV 1 ) z-score −3.55±1.30) and elevated airway resistance (R5 Hz 165.8±53.64%). Peak oxygen consumption ( V′ O 2 peak ) was 36.8±8.58 mL·kg −1 ·min −1 (47% ≤10 percentile) and breathing reserve 7.08±8.29%, indicating ventilatory limitation. Handgrip strength was 0.49±0.14 kg·kg −1 . The 30-s STS test was 27.2±5.7 repetitions. PAQ-A/PAQ-C was 1.89±0.46 indicating a low physical activity level. SGRQ was 20.1±10.8%. There was no resting dyspnoea. Multivariate regression identified significant associations between V′ O 2 peak and FEV 1 (p<0.001), BMI (p<0.001), SGRQ (p=0.005), female sex (p=0.002) and age (p=0.033). Conclusions: In these patients, cardiorespiratory fitness was impaired mainly due to ventilatory limitations. Lung function, upper and lower limb muscle strength, BMI, quality of life, sex and age were all associated with fitness level.
- 17 July 2025
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 11 (6)
Open AccessCardiorespiratory fitness in patients with post-infectious bronchiolitis obliterans: a cross-sectional study
Background: Post-infectious bronchiolitis obliterans (PIBO) arises after lower respiratory tract infection during childhood and is marked by impaired lung function. Despite possible impacts on exercise capacity, cardiorespiratory fitness in PIBO patients remain largely unknown. This study aimed to examine cardiorespiratory fitness and identify possible demographic and clinical–functional associations. Methods: The following variables were examined in a multicentre, cross-sectional study conducted in clinically stable PIBO patients aged 6–20 years: cardiorespiratory fitness (exercise testing), lung function (spirometry and impulse oscillometry), muscle strength (handgrip, upper and lower extremities), functional capacity (30-s sit-to-stand (STS) test), physical activity level (physical activity questionnaire adolescents and children; PAQ-A-C), body mass index (BMI), quality of life (Saint George's respiratory questionnaire; SGRQ) and dyspnoea perception (modified Medical Research Council scale). Results: 51 patients were enrolled (mean age 13.2±4.2 years, 49% female). BMI z-score was 0.06±1.20. Lung function tests indicated moderate-to-severe obstruction (forced expiratory volume in 1 s (FEV 1 ) z-score −3.55±1.30) and elevated airway resistance (R5 Hz 165.8±53.64%). Peak oxygen consumption ( V′ O 2 peak ) was 36.8±8.58 mL·kg −1 ·min −1 (47% ≤10 percentile) and breathing reserve 7.08±8.29%, indicating ventilatory limitation. Handgrip strength was 0.49±0.14 kg·kg −1 . The 30-s STS test was 27.2±5.7 repetitions. PAQ-A/PAQ-C was 1.89±0.46 indicating a low physical activity level. SGRQ was 20.1±10.8%. There was no resting dyspnoea. Multivariate regression identified significant associations between V′ O 2 peak and FEV 1 (p<0.001), BMI (p<0.001), SGRQ (p=0.005), female sex (p=0.002) and age (p=0.033). Conclusions: In these patients, cardiorespiratory fitness was impaired mainly due to ventilatory limitations. Lung function, upper and lower limb muscle strength, BMI, quality of life, sex and age were all associated with fitness level.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- 8 April 2023
- Published by Wiley in Pediatric Allergy and Immunology
- Vol. 34 (4) , e13942
Cost‐effectiveness of omalizumab for the treatment of severe pediatric allergic asthma—Results of a real‐life study in Spain
Background: Severe pediatric allergic asthma (SPAA) induces a huge economic burden in terms of direct, indirect, and intangible costs. The use of omalizumab for the treatment of these patients has produced a significant improvement in several clinical outcomes, but at the same time, the cost for the management of the disease has also increased. The aim of this report was to evaluate whether the use of omalizumab is cost‐effective.Methods: A sample of 426 children with SPAA from the ANCHORS (Asthma iN CHildren: Omalizumab in Real‐life in Spain) study was used to calculate the incremental cost‐effectiveness ratio (ICER) for the avoidance of moderate‐to‐severe exacerbations (MSE) and also for the improvement in childhood Asthma Control Test (c‐ACT) or the Asthma Control Questionnaire (ACQ5). We retrospectively collected data on health encounters and drug consumption before and up to 6 years after the beginning of the treatment with omalizumab.Results: The ICER per avoided MSE was €2107 after 1 year, and it consistently decreased to €656 in those followed up to 6 years. Similarly, the ICER for the minimally important difference in control tests showed a decrease from €2059 to €380 per each 0.5 points of improvement in ACQ5 and from €3141 to €2322 per each 3 points improvement in c‐ACT, at years 1 and 6, respectively.Conclusion: The use of OMZ is a cost‐effective option for most children with uncontrolled SPAA, especially those who have frequent exacerbations; the costs are progressively reduced in successive years of treatment.
- Open Access
- 6 March 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 19 (8) , 798-804
Inhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma
- 6 March 2023
- Published by Springer Nature in World Journal of Pediatrics
- Vol. 19 (8) , 798-804
Open AccessInhaler Technique Questionnaire (InTeQ) in pediatric patients with asthma
- Open Access
- 1 January 2022
- Published by Wiley in Clinical & Translational Immunology
- Vol. 11 (2) , e1376
Epigenetic regulation of inflammation by microRNAs in post‐infectious bronchiolitis obliterans
Objectives: Post‐infectious bronchiolitis obliterans (PiBO) is a rare, chronic disease initiated by severe infection and followed by perpetuating inflammation and obliteration of the small airways. MicroRNAs (miRNAs) have been proposed to play a central role as epigenetic regulators, which control resolution and prevent the uncontrolled progress of inflammation. The aim of this study was to define biomarkers on the level of post‐transcriptional gene regulation in order to characterise PiBO.Methods: A total of 39 patients with well‐defined PiBO and 31 controls from two centres, Barcelona, Spain, and Frankfurt, Germany, were analysed by next‐generation sequencing (NGS). The evaluation of the biological targets of the miRNAs was performed by pathway enrichment analysis and protein–protein interaction network analysis respectively.Results: Patients with PiBO had significantly lower lung function values and increased airway inflammation in induced sputum as indicated by total cell counts, neutrophils, IL‐1β, IL‐6, IL‐8 and TGF‐β compared to controls.Next‐generation sequencing analysis revealed a total of 22 dysregulated miRNAs, which passed significance threshold for Padj ≤ 0.001 with 17 being upregulated and 5 being downregulated. Of these dysregulated miRNAs, miR‐335‐5p, miR‐186‐5p, miR‐30b‐5p and miR‐30c‐5p were further validated using qRT‐PCR. Interestingly, these miRNAs are functionally implicated in cytokine–cytokine receptor interaction, TGF‐β signalling and FoxO signalling pathway and significantly correlated with lung function values (FEV1).Conclusion: Our results demonstrate an aberrant miRNA expression profile in PiBO, which impacts pathways responsible for the regulation of inflammation and fibrosis. The defined miRNAs are useful biomarkers and should be assessed as potential target in the field of miRNA therapeutics.
- 1 January 2022
- Published by Wiley in Clinical & Translational Immunology
- Vol. 11 (2) , e1376
Open AccessEpigenetic regulation of inflammation by microRNAs in post‐infectious bronchiolitis obliterans
Objectives: Post‐infectious bronchiolitis obliterans (PiBO) is a rare, chronic disease initiated by severe infection and followed by perpetuating inflammation and obliteration of the small airways. MicroRNAs (miRNAs) have been proposed to play a central role as epigenetic regulators, which control resolution and prevent the uncontrolled progress of inflammation. The aim of this study was to define biomarkers on the level of post‐transcriptional gene regulation in order to characterise PiBO.Methods: A total of 39 patients with well‐defined PiBO and 31 controls from two centres, Barcelona, Spain, and Frankfurt, Germany, were analysed by next‐generation sequencing (NGS). The evaluation of the biological targets of the miRNAs was performed by pathway enrichment analysis and protein–protein interaction network analysis respectively.Results: Patients with PiBO had significantly lower lung function values and increased airway inflammation in induced sputum as indicated by total cell counts, neutrophils, IL‐1β, IL‐6, IL‐8 and TGF‐β compared to controls.Next‐generation sequencing analysis revealed a total of 22 dysregulated miRNAs, which passed significance threshold for Padj ≤ 0.001 with 17 being upregulated and 5 being downregulated. Of these dysregulated miRNAs, miR‐335‐5p, miR‐186‐5p, miR‐30b‐5p and miR‐30c‐5p were further validated using qRT‐PCR. Interestingly, these miRNAs are functionally implicated in cytokine–cytokine receptor interaction, TGF‐β signalling and FoxO signalling pathway and significantly correlated with lung function values (FEV1).Conclusion: Our results demonstrate an aberrant miRNA expression profile in PiBO, which impacts pathways responsible for the regulation of inflammation and fibrosis. The defined miRNAs are useful biomarkers and should be assessed as potential target in the field of miRNA therapeutics.
- 1 January 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (1) , 22-29
Incidence and Prevalence of Children's Diffuse Lung Disease in Spain
- 1 January 2022
- Published by Elsevier in Archivos de Bronconeumología
- Vol. 58 (1) , 22-29
Incidence and Prevalence of Children's Diffuse Lung Disease in Spain
- Open Access
- 14 December 2020
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (5) , 1205-1214
Respiratory outcomes of “new” bronchopulmonary dysplasia in adolescents: A multicenter study
Objective: Long‐term respiratory consequences of bronchopulmonary dysplasia (BPD) in preterm infants born in the post‐surfactant era (“new” BPD) remain partially unknown. The present study aimed to evaluate the respiratory outcomes of “new” BPD in adolescents who were born preterm.Methods: This multicenter, cross‐sectional study included 286 adolescents born between 2003 and 2005 (mean age: 14.2 years); among them, 184 and 102 were born extremely preterm (EP; 1), forced vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow between 25% and 75% of FVC than other included adolescents. FEV1/FVC ratios were below the lower limit of normal (z‐score <−1.645) in 30.4% of EP adolescents with BPD, 13.0% of EP adolescents without BPD, and 11.8% of adolescents who were born moderate–late preterm. Bronchodilator response and air‐trapping were significantly higher in BPD adolescents than in other adolescents. Diffusion capacity was significantly lower in EP adolescents than in moderate–late preterm adolescents. Asthma symptoms and quality‐of‐life scores were similar among groups.Conclusion: EP adolescents with “new” BPD had poorer pulmonary function than EP adolescents without BPD or moderate–late preterm adolescents. Further studies are needed to determine whether “new” BPD is associated with early‐onset chronic obstructive pulmonary disease in adulthood.
- 14 December 2020
- Published by Wiley in Pediatric Pulmonology
- Vol. 56 (5) , 1205-1214
Open AccessRespiratory outcomes of “new” bronchopulmonary dysplasia in adolescents: A multicenter study
Objective: Long‐term respiratory consequences of bronchopulmonary dysplasia (BPD) in preterm infants born in the post‐surfactant era (“new” BPD) remain partially unknown. The present study aimed to evaluate the respiratory outcomes of “new” BPD in adolescents who were born preterm.Methods: This multicenter, cross‐sectional study included 286 adolescents born between 2003 and 2005 (mean age: 14.2 years); among them, 184 and 102 were born extremely preterm (EP; 1), forced vital capacity (FVC), FEV1/FVC ratio, and forced expiratory flow between 25% and 75% of FVC than other included adolescents. FEV1/FVC ratios were below the lower limit of normal (z‐score <−1.645) in 30.4% of EP adolescents with BPD, 13.0% of EP adolescents without BPD, and 11.8% of adolescents who were born moderate–late preterm. Bronchodilator response and air‐trapping were significantly higher in BPD adolescents than in other adolescents. Diffusion capacity was significantly lower in EP adolescents than in moderate–late preterm adolescents. Asthma symptoms and quality‐of‐life scores were similar among groups.Conclusion: EP adolescents with “new” BPD had poorer pulmonary function than EP adolescents without BPD or moderate–late preterm adolescents. Further studies are needed to determine whether “new” BPD is associated with early‐onset chronic obstructive pulmonary disease in adulthood.
- Open Access
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3603
Immunofluorescence Analysis as a Diagnostic Tool in a Spanish Cohort of Patients with Suspected Primary Ciliary Dyskinesia
Primary ciliary dyskinesia (PCD) is an autosomal recessive rare disease caused by an alteration of ciliary structure. Immunofluorescence, consisting in the detection of the presence and distribution of cilia proteins in human respiratory cells by fluorescence, has been recently proposed as a technique to improve understanding of disease-causing genes and diagnosis rate in PCD. The objective of this study is to determine the accuracy of a panel of four fluorescently labeled antibodies (DNAH5, DNALI1, GAS8 and RSPH4A or RSPH9) as a PCD diagnostic tool in the absence of transmission electron microscopy analysis. The panel was tested in nasal brushing samples of 74 patients with clinical suspicion of PCD. Sixty-eight (91.9%) patients were evaluable for all tested antibodies. Thirty-three cases (44.6%) presented an absence or mislocation of protein in the ciliary axoneme (15 absent and 3 proximal distribution of DNAH5 in the ciliary axoneme, 3 absent DNAH5 and DNALI1, 7 absent DNALI1 and cytoplasmatic localization of GAS8, 1 absent GAS8, 3 absent RSPH9 and 1 absent RSPH4A). Fifteen patients had confirmed or highly likely PCD but normal immunofluorescence results (68.8% sensitivity and 100% specificity). In conclusion, immunofluorescence analysis is a quick, available, low-cost and reliable diagnostic test for PCD, although it cannot be used as a standalone test.
- 9 November 2020
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (11) , 3603
Open AccessImmunofluorescence Analysis as a Diagnostic Tool in a Spanish Cohort of Patients with Suspected Primary Ciliary Dyskinesia
Primary ciliary dyskinesia (PCD) is an autosomal recessive rare disease caused by an alteration of ciliary structure. Immunofluorescence, consisting in the detection of the presence and distribution of cilia proteins in human respiratory cells by fluorescence, has been recently proposed as a technique to improve understanding of disease-causing genes and diagnosis rate in PCD. The objective of this study is to determine the accuracy of a panel of four fluorescently labeled antibodies (DNAH5, DNALI1, GAS8 and RSPH4A or RSPH9) as a PCD diagnostic tool in the absence of transmission electron microscopy analysis. The panel was tested in nasal brushing samples of 74 patients with clinical suspicion of PCD. Sixty-eight (91.9%) patients were evaluable for all tested antibodies. Thirty-three cases (44.6%) presented an absence or mislocation of protein in the ciliary axoneme (15 absent and 3 proximal distribution of DNAH5 in the ciliary axoneme, 3 absent DNAH5 and DNALI1, 7 absent DNALI1 and cytoplasmatic localization of GAS8, 1 absent GAS8, 3 absent RSPH9 and 1 absent RSPH4A). Fifteen patients had confirmed or highly likely PCD but normal immunofluorescence results (68.8% sensitivity and 100% specificity). In conclusion, immunofluorescence analysis is a quick, available, low-cost and reliable diagnostic test for PCD, although it cannot be used as a standalone test.